

Kirsi Norrbacka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6371300/publications.pdf>

Version: 2024-02-01

9
papers

174
citations

1162367
8
h-index

1473754
9
g-index

9
all docs

9
docs citations

9
times ranked

171
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucagon-Like Peptide-1 Receptor Agonists in Type-2 Diabetes Mellitus: Data from a Real-World Study in Spain. <i>Diabetes Therapy</i> , 2021, 12, 1535-1551.	1.2	10
2	Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. <i>European Journal of Health Economics</i> , 2020, 21, 1179-1196.	1.4	8
3	GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. <i>Diabetes Therapy</i> , 2019, 10, 1067-1088.	1.2	33
4	Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2019, 35, 893-901.	0.9	16
5	Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. <i>Diabetes Therapy</i> , 2018, 9, 789-801.	1.2	28
6	The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. <i>Diabetes Therapy</i> , 2018, 9, 13-25.	1.2	11
7	GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. <i>Diabetes Therapy</i> , 2017, 8, 115-128.	1.2	30
8	The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥ 30 kg/m ² . <i>Journal of Medical Economics</i> , 2017, 20, 443-452.	1.0	14
9	The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥ 30 kg/m ² in Spain. <i>Journal of Medical Economics</i> , 2013, 16, 926-938.	1.0	24